Your browser doesn't support javascript.
loading
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Gajjar, Amar; Mahajan, Anita; Abdelbaki, Mohamed; Anderson, Clarke; Antony, Reuben; Bale, Tejus; Bindra, Ranjit; Bowers, Daniel C; Cohen, Kenneth; Cole, Bonnie; Dorris, Kathleen; Ermoian, Ralph; Franson, Andrea; Helgager, Jeffrey; Landi, Daniel; Lin, Chi; Metrock, Laura; Nanda, Ronica; Palmer, Joshua; Partap, Sonia; Plant, Ashley; Pruthi, Sumit; Reynolds, Renee; Ruggieri, Paul; Stearns, Duncan; Storm, Phillip; Wang, Anthony; Warren, Katherine; Whipple, Nicholas; Zaky, Wafik; McMillian, Nicole R; Pluchino, Lenora A.
Afiliación
  • Gajjar A; 1St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
  • Mahajan A; 2Mayo Clinic Cancer Center.
  • Abdelbaki M; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Anderson C; 4City of Hope National Medical Center.
  • Antony R; 5UC Davis Comprehensive Cancer Center.
  • Bale T; 6Memorial Sloan Kettering Cancer Center.
  • Bindra R; 7Yale Cancer Center/Smilow Cancer Hospital.
  • Bowers DC; 8UT Southwestern Simmons Comprehensive Cancer Center.
  • Cohen K; 9The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Cole B; 10Fred Hutchinson Cancer Center.
  • Dorris K; 11University of Colorado Cancer Center.
  • Ermoian R; 10Fred Hutchinson Cancer Center.
  • Franson A; 12University of Michigan Rogel Cancer Center.
  • Helgager J; 13University of Wisconsin Carbone Cancer Center.
  • Landi D; 14Duke Cancer Institute.
  • Lin C; 15Fred & Pamela Buffett Cancer Center.
  • Metrock L; 16O'Neal Comprehensive Cancer Center at UAB.
  • Nanda R; 17Moffitt Cancer Center.
  • Palmer J; 18The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Partap S; 19Stanford Cancer Institute.
  • Plant A; 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Pruthi S; 21Vanderbilt-Ingram Cancer Center.
  • Reynolds R; 22University at Buffalo Neurosurgery.
  • Ruggieri P; 23Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Stearns D; 23Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Storm P; 24Abramson Cancer Center at the University of Pennsylvania.
  • Wang A; 25UCLA Jonsson Comprehensive Cancer Center.
  • Warren K; 26Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center.
  • Whipple N; 27Huntsman Cancer Institute at the University of Utah.
  • Zaky W; 28The University of Texas MD Anderson Cancer Center; and.
  • McMillian NR; 29National Comprehensive Cancer Network.
  • Pluchino LA; 29National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 20(12): 1339-1362, 2022 12.
Article en En | MEDLINE | ID: mdl-36509072
Central nervous system (CNS) cancers account for approximately one quarter of all pediatric tumors and are the leading cause of cancer-related death in children. More than 4,000 brain and CNS tumors are diagnosed each year in children and teens, and the incidence rate has remained stagnant in recent years. The most common malignant pediatric CNS tumors are gliomas, embryonal tumors consisting of predominately medulloblastomas, and germ cell tumors. The inaugural version of the NCCN Guidelines for Pediatric Central Nervous System Cancers focuses on the diagnosis and management of patients with pediatric diffuse high-grade gliomas. The information contained in the NCCN Guidelines is designed to help clinicians navigate the complex management of pediatric patients with diffuse high-grade gliomas. The prognosis for these highly aggressive tumors is generally poor, with 5-year survival rates of <20% despite the use of combined modality therapies of surgery, radiation therapy and systemic therapy. Recent advances in molecular profiling has expanded the use of targeted therapies in patients whose tumors harbor certain alterations. However, enrollment in a clinical trial is the preferred treatment for eligible patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Nervioso Central / Neoplasias de Células Germinales y Embrionarias / Glioma Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Adolescent / Child / Humans Idioma: En Revista: J Natl Compr Canc Netw Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Nervioso Central / Neoplasias de Células Germinales y Embrionarias / Glioma Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Adolescent / Child / Humans Idioma: En Revista: J Natl Compr Canc Netw Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos